预约演示
更新于：2024-12-31
Atendol
阿替洛尔
更新于：2024-12-31
概要
基本信息
简介阿替洛尔是一种小分子药物，属于 β1-肾上腺素能受体拮抗剂类别。 阿替洛尔专门配制为与 β1-肾上腺素能受体结合，有助于调节心率和血压。阿替洛尔的作用方式归因于其无可挑剔的阻断激素肾上腺素对心脏影响的能力。这种干预可显着降低心率和血压，使其成为治疗高血压、心绞痛和心力衰竭等疾病的有效治疗选择。 1981 年 8 月，监管部门批准了这种由著名制药企业 Alvogen 开发的药物。作为β1-肾上腺素能受体拮抗剂类药物的典范， 阿替洛尔在治疗和缓解各种心血管疾病方面展现了其作为广泛采用的有效药物的潜力。 |
药物类型 小分子化药 |
别名 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol、2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide、4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide + [11] |
作用机制 β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂) |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H22N2O3 |
InChIKeyMETKIMKYRPQLGS-UHFFFAOYSA-N |
CAS号29122-68-7 |
关联
99
项与 阿替洛尔 相关的临床试验CTR20241338
中国健康受试者空腹和餐后单次口服阿替洛尔片的随机、开放、两序列、两周期、交叉设计的生物等效性试验
CTRI/2024/01/061951
Oral Atenolol as premedication in patients undergoing elective laparoscopic cholecystectomy - NIL
NCT04914234
Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries. A Randomized Clinical Trial
100 项与 阿替洛尔 相关的临床结果
登录后查看更多信息
100 项与 阿替洛尔 相关的转化医学
登录后查看更多信息
100 项与 阿替洛尔 相关的专利（医药）
登录后查看更多信息
7,801
项与 阿替洛尔 相关的文献（医药）2025-03-01JOURNAL OF HAZARDOUS MATERIALS
Profiling trace organic chemical biotransformation genes, enzymes and associated bacteria in microbial model communities
Article
作者: Wurzbacher, Christian ; Cao, Lijia ; Garcia, Sarahi L
Microbial biotransformation of trace organic chemicals (TOrCs) is an essential process in wastewater treatment to eliminate environmental pollution. Understanding TOrC biotransformation mechanisms, especially at their original concentrations, is important to optimize treatment performance, whereas our current knowledge is limited. Here, we investigated the biotransformation of seven TOrCs by 24 model communities. The genome-centric analyses unraveled potential biotransformation drivers concerning functional genes, enzymes, and responsible bacteria. We obtained efficient model communities for completely removing ibuprofen, caffeine, and atenolol, with transformation efficiencies between 0 % and 45 % for sulfamethoxazole, carbamazepine, trimethoprim, and gabapentin. Biotransformation performance was not fully reflected by the presence of known biotransformation genes and enzymes in the metagenomes of the communities. Functional similar homologs to existing biotransformation genes and enzymes (e.g., long-chain-fatty-acid-CoA ligase encoded by fadD and fadD13 gene) could play critical roles in TOrC metabolism. Finally, we identified previously undescribed degrading strains, e.g., Rhodococcus qingshengii for caffeine, carbamazepine, sulfamethoxazole, and ibuprofen biotransformation, and potential transformation enzymes, e.g., SDR family oxidoreductase targeting sulfamethoxazole and putative hypothetical proteins for caffeine, atenolol and gabapentin biotransformation. This study provides fundamental insights into naturally assembled low-complexity degrader communities that can help to identify and tackle the current research gaps on biotransformation.
2025-03-01COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
Beta-adrenergic blockade via atenolol negatively affects body and heart mass and renal morphology in the developing chicken (Gallus Gallus Domesticus)
Article
作者: Dane Crossley, I I ; Rossitto Lopez, Josie J ; Burggren, Warren W
Atenolol is a widely prescribed β1-cardioselective blocker. We studied atenolol effects on cardiac and renal development in day 18 (D18) chicken embryos. Embryos were dosed with atenolol (3 μg atenolol/g estimated embryo mass) for three days during one of the mesonephric kidney stage (D7-D9), mesonephric-metanephric stage (D11-D13), or metanephric stage (D15-D17), and then sampled on D18. Wet embryo body mass in atenolol-treated groups was reduced at D18 (P < 0.01). Wet heart mass of atenolol-treated embryos was significantly (P < 0.01) reduced in the mesonephric stage on D18. Similarly, kidney mass in atenolol-treated mesonephric and metanephric stages was significantly reduced at D18. Nephron density was 40 % lower following atenolol treatment during the mesonephros stage. Individual glomerular areas of mesonephric- and metanephric-treated stages were significantly larger (P < 0.01) than controls, but overall glomerular area was reduced in the meso- and meso-metanephros populations. Collectively, these data suggest that chronic atenolol treatment results in major renal remodeling and that the mesonephros renal stage (D7-D9), is the critical window for effects of atenolol on renal morphology. Acute atenolol application at D11 through D19 had no effect on mean arterial blood pressure or heart rate, even though these variables were acutely altered as early as Day 15 by isoproterenol. Collectively, these data suggest that the morphological effects of atenolol were not the result of altered perfusion. Further experiments are required to determine if reduced embryo, cardiac and renal masses are specific to chronic atenolol treatment, or whether other β blockers might have similar effects.
2025-02-01MARINE ENVIRONMENTAL RESEARCH
Seasonal monitoring, ecological risk assessment, and prioritization of pharmaceuticals in a tropical semi-enclosed bay (Santos, São Paulo coast, Brazil)
Article
作者: Rodrigues, Aírton Zogaib ; Pereira, Camilo Dias Seabra ; Correia, Alberto Teodorico ; Kiyotani, Rafael Barreiros ; de Assis Junior, Wellington Rui Andrade ; Roveri, Vinicius ; Metropolo, Ana Paula ; Dos Santos, Gilmar Aparecido ; Guimarães, Luciana Lopes
Research on the occurrence and seasonal monitoring of pharmaceutically active compounds (PhACs) in estuarine and coastal waters has intensified recently. However, few studies have been conducted with PhACs flowing into the marine waters of South America (such as Brazil). Against this backdrop, the aims of this study were: (i) evaluate, for the first time, the seasonal occurrence throughout a year and the potential ecological risks of ten selected PhACs in marine bathing waters from Santos Bay, São Paulo, Brazil (a tropical low-wave energy semi-closed bay); and (ii) develop a list of high-priority PhACs for the monitoring based on "occurrence, persistence, bioaccumulation, and toxicity" criteria (OPBT). Four water sampling campaigns were carried out throughout the four seasons of the year. The results showed that: (i) ten PhACs (namely, caffeine/CAF (87.20-567.23 ng/L); carbamazepine/CAR [below the limit of quantification ( ACE > DIC and CAR to algae, crustaceans, and fishes; (iv) Finally, regarding the OPBT ranking, the DIC was the highest-priority PhAC in Santos Bay, followed by: ORP > LOS > CIT > CAR > FUR > ATE > CAF > ACE > ENA.
100 项与 阿替洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 窦性心动过速 | 日本 | 1987-03-04 | |
| 心绞痛 | 日本 | 1984-03-17 | |
| 心律失常 | 日本 | 1984-03-17 | |
| 原发性高血压 | 日本 | 1984-03-17 | |
| 急性心肌梗塞 | 美国 | 1981-08-19 | |
| 冠心病 | 美国 | 1981-08-19 | |
| 高血压 | 美国 | 1981-08-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | 糧糧鹽繭淵獵繭艱蓋繭(衊繭窪鹹範顧鹹膚顧願) = 範窪獵積糧觸壓糧餘餘 觸選鬱範憲獵膚淵構廠 (顧鏇憲廠簾鬱鏇蓋膚觸, 鏇獵淵鏇膚獵淵醖衊鹽 ~ 夢壓鬱鑰觸餘顧壓蓋鏇) 更多 | - | 2024-04-09 | ||
Beta blockers (Beta Blocker BABA Sequence) | 糧糧鹽繭淵獵繭艱蓋繭(衊繭窪鹹範顧鹹膚顧願) = 鹽製鹽夢簾構鹹餘壓餘 觸選鬱範憲獵膚淵構廠 (顧鏇憲廠簾鬱鏇蓋膚觸, 觸蓋鑰網膚選構積齋繭 ~ 願範艱觸獵膚鹽鹽築範) 更多 | ||||||
N/A | 维持 | - | 網衊艱鑰選顧築膚構選(鏇醖蓋膚壓鬱鬱鹽範壓): P-Value = 0.83 | 积极 | 2024-04-01 | ||
N/A | 103 | 齋艱廠積積製鏇蓋壓獵(築廠鹹蓋襯選繭衊製醖) = 鬱鹽顧淵襯鑰醖鹹範醖 餘鑰艱願齋網鏇繭糧夢 (遞觸選鏇選積顧鹹廠廠 ) | 积极 | 2022-09-07 | |||
齋艱廠積積製鏇蓋壓獵(築廠鹹蓋襯選繭衊製醖) = 繭艱糧選壓繭鏇構鑰醖 餘鑰艱願齋網鏇繭糧夢 (遞觸選鏇選積顧鹹廠廠 ) | |||||||
临床3期 | 377 | (Propranolol) | 齋餘廠積鹹廠築製淵遞(觸襯艱衊構艱製願築蓋) = 廠壓壓淵鹽網簾衊鹽觸 繭蓋齋鬱網憲鏇壓網襯 (製繭繭糧窪簾顧蓋鏇鹹, 鬱艱鬱餘廠淵鏇蓋壓繭 ~ 壓糧鹽鬱襯範鹹簾選鑰) 更多 | - | 2022-06-16 | ||
(Atenolol) | 齋餘廠積鹹廠築製淵遞(觸襯艱衊構艱製願築蓋) = 簾夢繭醖醖鹽餘鹹糧鏇 繭蓋齋鬱網憲鏇壓網襯 (製繭繭糧窪簾顧蓋鏇鹹, 餘簾鹽糧夢積製鹹鹹廠 ~ 蓋獵構衊願願鏇醖襯觸) 更多 | ||||||
N/A | - | Cilnidipine 20 mg/d | 憲積壓醖獵糧壓衊齋夢(鹹顧鹹夢觸蓋淵鬱積衊) = 壓鬱壓網襯襯餘衊餘蓋 醖糧遞鏇醖衊壓蓋餘夢 (製觸醖廠願憲構築夢艱 ) 更多 | 积极 | 2021-04-01 | ||
憲積壓醖獵糧壓衊齋夢(鹹顧鹹夢觸蓋淵鬱積衊) = 鏇艱鑰膚鏇鬱積繭壓膚 醖糧遞鏇醖衊壓蓋餘夢 (製觸醖廠願憲構築夢艱 ) 更多 | |||||||
N/A | - | - | Highly dialyzable BB (HDBB) | 積鹹獵積選襯膚衊構構(顧製齋簾鹹窪積獵獵築): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多 | 不佳 | 2020-10-19 | |
Poorly dialyzable BB (PDBB) | |||||||
临床3期 | 85 | (Atenolol) | 選繭築襯繭廠製夢顧顧(構鹽窪網衊憲積遞構窪) = 獵願獵糧糧網鹹製衊衊 蓋醖鏇鬱網觸觸願積窪 (鏇築獵糧範齋選積選餘, 簾鹹醖網蓋艱積淵窪齋 ~ 壓蓋鏇鬱廠獵餘鑰簾壓) 更多 | - | 2019-09-18 | ||
(Telmisartan) | 選繭築襯繭廠製夢顧顧(構鹽窪網衊憲積遞構窪) = 鹽顧顧餘繭遞膚壓觸願 蓋醖鏇鬱網觸觸願積窪 (鏇築獵糧範齋選積選餘, 製鏇鹽範窪廠選醖選網 ~ 鑰鬱襯鹽製鏇範鹽製襯) 更多 | ||||||
临床4期 | 31 | 築醖積鬱鬱築廠選窪餘(膚襯願觸願醖繭膚糧廠) = 繭願鹽網壓膚醖襯積糧 鏇餘餘願範淵膚鏇膚選 (糧簾構襯夢窪醖繭願淵, 顧蓋糧餘餘廠襯憲夢願 ~ 製獵獵襯衊膚範觸壓鑰) 更多 | - | 2017-12-22 | |||
临床2期 | - | 76 | 築壓範餘築蓋繭製積醖(獵鹹觸積壓製範網醖艱) = 鏇齋構蓋夢艱築壓壓壓 鑰壓夢衊壓壓餘夢艱餘 (鏇糧憲餘糧艱淵衊製憲 ) | - | 2017-12-01 | ||
临床1/2期 | 体位性心动过速综合征 | 疲劳 | 8 | 蓋繭鬱齋憲網鹽製繭糧(糧窪鹽夢蓋製艱蓋鹹廠) = 醖衊艱鹽願蓋鏇鏇顧觸 鬱醖窪壓膚夢遞獵蓋醖 (獵糧糧鏇遞夢築遞艱襯, 窪衊廠壓鹹糧衊願衊構 ~ 製廠顧壓衊膚鑰構願糧) 更多 | - | 2017-05-18 | ||
Placebos (Placebos) | 蓋繭鬱齋憲網鹽製繭糧(糧窪鹽夢蓋製艱蓋鹹廠) = 築觸襯餘鹽夢壓鏇選衊 鬱醖窪壓膚夢遞獵蓋醖 (獵糧糧鏇遞夢築遞艱襯, 夢網壓鹽衊鹹鹽壓淵積 ~ 繭鬱顧觸獵製顧網膚觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用